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Host defenses against viral infections depend on a complex interplay of innate (nonspeciﬁc) and adaptive (speciﬁc) components.
In the early stages of infection, innate mechanisms represent the main line of host defense, acting to limit the spread of virus in
host tissues prior to the induction of the adaptive immune response. Serum and lung ﬂuids contain a range of lectins capable
of recognizing and destroying inﬂuenza A viruses (IAV). Herein, we review the mechanisms by which soluble endogenous
lectins mediate anti-IAV activity, including their role in modulating IAV-induced inﬂammation and disease and their potential
as prophylactic and/or therapeutic treatments during severe IAV-induced disease.
1. GeneralFeaturesof Inﬂuenza Virus
Inﬂuenza virus causes a highly contagious, acute infection
of the upper and lower respiratory tract that is responsible
for millions of deaths annually, predominantly in the elderly
and in those with underlying pulmonary and cardiac disease
[1].InﬂuenzavirusesbelongtothefamilyOrthomyxoviridae,
which consists of type A, B, and C inﬂuenza viruses, Thogot-
ovirus,andIsavirus.Whileall3typesofinﬂuenzavirusinfect
humans, only inﬂuenza A viruses (IAVs) have the capacity
to induce both epidemics and pandemics. Type B inﬂuenza
viruses are associated with yearly epidemics whereas type C
viruses rarely cause severe disease [2].
IAV is an enveloped virus with a genome comprising 8
segments of single-stranded, negative sense RNA encoding
at least 10 proteins, including hemagglutinin (HA) and neu-
raminidase (NA), which are expressed on the virion surface.
HA and, to a lesser extent, NA represent major targets for
recognition by neutralizing antibodies and IAVs are divided
into subtypes based on serological and genetic diﬀerences
in their HA and NA proteins and the genes that encode
them. At present, at least 16 HA and 9 NA subtypes of
IAV have been identiﬁed, all of which are found amongst
aquatic birds [2, 3]. In humans, only certain HA (H1, H2,
andH3)andNA(N1andN2)subtypeshavebeeninvolvedin
epidemics and pandemics. Other subtypes of avian or equine
origin (e.g., H5N1, H7N7, and H9N2) have infected humans
but have not spread eﬃciently in the human population.
These ﬁndings do, however, highlight the potential for
mutation and/or genetic reassortment to facilitate entry and
transmission of novel IAV in the human population.
Antigenic variation is the mechanism by which new
subtypes or strains of IAV emerge in humans (reviewed in
[4]). Antigenic shift is the most profound type of antigenic
variation and results in the emergence of a virus that
possesses novel HA and/or NA, to which the human popu-
lation is immunologically na¨ ıve. Antigenic drift describes the
gradual accumulation of point mutations in the genome of
viruses that have been circulating in humans for an extended
time. Mutations in viral RNA can lead to changes in the
amino acid sequence of HA or NA and variants with changes
in key antigenic epitopes will be selected as they can escape
neutralization by preexisting antibodies. Antigenic variation
viashift(whichcanresultinpandemics)anddrift(whichcan2 Journal of Biomedicine and Biotechnology
resultinepidemics)ensurescontinuedpresenceofIAVinthe
human population despite immunity arising from previous
vaccination and/or infection.
1.1. Glycosylation of IAV Glycoproteins. T h eH Ai sat r i m e r i c
glycoprotein that mediates attachment of IAV to sialic acid
(SA)onhostcellsaswellasfusionoftheviralandendosomal
membranes during cell entry (reviewed in [5]). NA is a
tetramer that enzymatically cleaves SA from glycoproteins,
thereby facilitating release of progeny virions from the
surface of infected cells and preventing self-aggregation of
virus [6]. The “balance” between the receptor-binding and
receptor-destroyingactivitiesofHAandNA,respectively,isa
critical factor determining the eﬃciency of host cell infection
by diﬀerent IAV strains [7, 8].
Glycosylation of HA and NA occurs in the endoplasmic
reticulum (ER) and in the Golgi apparatus in a process
similar to that of host cell glycoproteins. HA/NA can express
a mixture of high mannose (branched structures terminat-
ing in mannose), complex (structures terminating in dif-
ferent combinations of galactose, N-acetyl-galactosamine
(GalNAc), fucose, or SA), or hybrid-type oligosaccharides
[9, 10]. Biosynthesis of N-glycans begins in the rough
endoplasmic reticulum (ER) with the transfer of a 14-
sugar precursor (usually comprising 3 glucose, 9 mannose,
and 2 N-acetyl-glucosamine (GlcNAc) molecules) from a
polyisoprenol derivative to the nascent polypeptide chain.
Transport of the glycoprotein is accompanied by trimming
of terminal glucose and mannose residues in the ER
and Golgi to generate high-mannose type glycans. Further
processing, including the attachment of additional GlcNAc,
fucose, galactose, and SA in the Golgi apparatus, results
in the generation of complex and hybrid-type glycans. The
oligosaccharides expressed on both HA and NA are exclu-
sively N-linked glycans attached to the Asn residue of Asn-
X-Ser/Thr, where X represents any amino acid except proline
[11, 12]. Complex oligosaccharides on IAV HA/NA are not
sialylated and bear terminal galactose/GlcNAc/fucose due to
r e m o v a lo ft e r m i n a lS Ab yt h ev i r a lN A[ 13].
Oligosaccharide diversity of HA/NA depends on the
number and location of potential N-glycosylation sites in
the viral genome as well as the size and composition of
the attached glycans. Certain regions of HA have conserved
glycosylation sites or must remain free of oligosaccharides
for the formation, transport, and/or maintenance of func-
tional HA. The combinations of high-mannose, complex,
and hybrid type glycans present on IAV glycoproteins are
also determined by the particular biosynthetic and trimming
enzymes provided by the host cell in which the virus
was grown [14]. Acquisition of glycosylation sites on HA
through antigenic drift has been proposed to mask or
modify antigenic sites, thereby preventing recognition by
neutralizing antibodies elicited to previous virus strains
[15–17]. Consequently, pandemic IAV strains derived from
zoonotic reservoirs generally have fewer potential N-linked
glycosylation sites on the head of HA compared to seasonal
IAV strains that have circulated in the human population
for many years [17–19]. In addition to increased numbers,
positional conversion of glycosylation sites (i.e., acquisition
of a new glycosylation site accompanied by loss of an existing
site) represents an additional mechanism proposed to favour
evasion of antibody-mediated immunity and therefore per-
sistence of IAV in humans [18]. The presence of potential
N-linked glycosylation sites in the amino acid sequence of
HA does not always correspond to the presence of attached
glycans and some sites may not be glycosylated eﬃciently. To
date,thedetailedstructureoftheglycanscarriedatparticular
glycosylation sites has not been well established for most
strains of IAV.
2.GeneralFeaturesof AnimalLectins
Lectins are nonenzymatic proteins that bind selectively to
speciﬁc carbohydrate structures. Over the last 20 years,
numerous lectins have been isolated and characterized from
mammals, birds, and other animals. Unlike plant lectins,
which are often grouped into families based on taxonomy,
animal lectins often exhibit structural similarities even when
derivedfromdiversephyla.Therefore,animallectinsaregen-
erally classiﬁed on the basis of an evolutionarily conserved
carbohydrate recognition domain (CRD) [20] and on this
basis they can be grouped into families, including C-type,
S-type (or galectins), P-type (or Man-6-P lectins), Ig-type
(or Siglecs), R-type, and F-type lectins (reviewed in [21]).
Other lectins do not contain these CRDs but have evolved
equivalent carbohydrate-binding characteristics, including
pentraxins and glycosaminoglycan-binding proteins. C-type
and S-type lectins, as well as pentraxins, have been reported
to display lectin-mediated anti-IAV activity in vitro and/or in
vivo and will be discussed further in this review.
2.1.C-TypeLectins. C-typelectinsareafamilyofanimalpro-
teins that display Ca2+-dependent (C-type) carbohydrate-
binding activity and mediate a range of biological processes
including endocytosis, cell-to-cell adhesion, turnover of
serum glycoproteins, and pathogen recognition. The C-
type lectin CRD contains conserved residue motifs that are
characteristic of the domain and are responsible for Ca2+-
dependent binding activity [20, 22]. In general terms, C-
type lectins bind either derivatives of mannose (Man-type
ligands) or galactose (Gal-type ligands) [22, 23]a n dm a y
be further subdivided into endocytic lectins and collectins
on the basis of structural similarities. Endocytic C-type
lectins include type I (e.g., macrophage mannose receptor
(MMR)) and type II (e.g., macrophage galactose-type lectin
(MGL) and DC-speciﬁc ICAM-3 grabbing non-integrin
(DC-SIGN)) transmembrane proteins and these have been
implicated as attachment and entry receptors for IAV
infection [24, 25]. The collectins, so called because of their
collagenous domains, are soluble C-type lectins that have
beenimplicatedasamajorcomponentofinnatehostdefense
against IAV infection (Figure 1). The mechanisms by which
collectins mediate anti-IAV activity, their role in innate
host defense, and their potential as therapeutic agents to
ameliorate IAV-induced disease will be discussed further in
this paper.Journal of Biomedicine and Biotechnology 3
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Figure 1: Subunit organization and assembly of mammalian lectins with antiviral activity against IAV. (a) Soluble C-type lectins of the
collectin superfamily. Collectin subunits are comprised of 3 identical or similar polypeptide chains associated together to form triple helices.
Each polypeptide chain bears a C-terminal CRD attached to a short “neck” region, a longer collagenous domain, and a noncollagenous
N-terminal domain. CL-43 exists as a trimer whereas other collectins associate together to form multimers with characteristic “cruciform-
like” (e.g., SP-D or conglutinin) or “bouquet-like” structures (e.g., MBL, SP-A) or higher-order oligomers (e.g., SP-D). (b) S-type lectins
or galectins are a family of β-galactosidase-binding lectins containing homologous CRDs. Galectin-1 consists of a single CRD and a short
N-terminal sequence and can form noncovalent dimers. (c) Pentraxin subunits are characterized by an 8 amino acid pentraxin signature
(H-x-C-x-S/T-W-x-S/T, where x is any amino acid). Subunits assemble into multimers, usually noncovalently associated pentameric or
decameric structures.
2.2. S-Type Lectins. S-type lectins, also known as galectins,
do not require divalent cations for ligand binding, display
speciﬁcity for β-galactosyl-containing glycoconjugates, and
mediate a diverse range of biological functions (Figure 1;
reviewed in [26]). They are widely distributed among animal
tissues and may be located both inside (in the cytoplasm
and/or nucleus) and outside cells (on the cell surface and/or
within extracellular spaces). To date, 15 galectins have been
identiﬁed,allofwhichcontainaconservedCRD(reviewedin
[27]). Galectin-1, -3, -8, and -9 are found in human airways,
the primary site of IAV infection. Recently, galectin-1 was
implicated as an eﬀector in innate host defense during IAV
infection [28].
2.3. Pentraxins. Like collectins, the pentraxins are a family
of lectin-like proteins highly conserved during evolution and
characterized by a multimeric (usually pentameric) struc-
ture. The classic short pentraxins, C-reactive protein (CRP)
andserumamyloidP-component(SAP),areproducedbythe
liver in response to inﬂammatory signals and are the main
acute phase reactants in human and mouse, respectively
[29]. Moreover, they share a structural organization that
comprises 5 or 10 identical units arranged in a pentameric
radial symmetry (Figure 1). PTX3, the prototype of the
long pentraxins, shares similarities with short pentraxins
but contains an unrelated N-terminal domain, is produced
by diﬀerent cell types, and binds to a diﬀerent spectrum
of ligands [30]. Pentraxins display lectin-like properties,
including binding to carbohydrates and related structures in
aC a 2+-dependent manner. SAP was originally isolated based
on its ability to bind to the 4,6-cyclin pyruvate acetal group
of β-D-galactose [31] and has also been implicated in lectin-
mediated interactions with IAV [32, 33].
3.Collectins inInnateHost Defense
againstInﬂuenza VirusInfection
Collectins are present in serum and mucosal secretions and
recognize particular patterns of carbohydrates expressed on
the surface of bacteria, fungi, protozoa, and viruses. To date,
nine distinct collectins have been identiﬁed: surfactant pro-
tein (SP)-A, SP-D, mannose-binding lectin (MBL), collectin
placenta 1 (CL-P1), collectin liver 1 (CL-L1), and collectin
kidney 1 (CL-K1 or collectin-11) as well as the bovine-
speciﬁc collectins CL-43, CL-46, and conglutinin. The basic
structural unit of collectins is a trimer of 3 associated4 Journal of Biomedicine and Biotechnology
Table 1: Comparison of monosaccharide speciﬁcity of animal lectins with anti-IAV activity.
Lectina Family Monosaccharide preferencesb Binding to IAV
hSP-D C-type L-Fuc > Mann > Gluc > Gal > GlcNAc [142]Y e s
hMBL C-type GlcNAc > L-Fuc, Mann > ManNAc > Gluc > GalNAc [74]Y e s
hCL-L1 C-type Mann = L-Fuc = Gal > GlcNAc > GalNAc [94]—
hCL-K1 C-type L-Fuc > Mann > ManNAc > GlcNAc > Gal [96]Y e s
bConglutinin C-type GlcNAc > Mann, L-Fuc > Gluc > ManNAc > GalNAc [74]Y e s
bCL-43 C-type Mann > ManNAc > L-Fuc > GlcNAc > Gluc > GalNAc [112]Y e s
bCL-46 C-type GlcNAc > ManNAc > Mann, Gluc, L-Fuc > Gal [143]Y e s
hGalectin-1 S-type Gal > GalNAc > GlcNAc, Mann [144]Y e s
hSAP Pentraxin Mann > GlcNAc > L-Fuc, Gal, GalNAc [32]Y e s
aData reported for human (h) or bovine (b) lectins as indicated.
bAbbreviation of monosaccharides: L-Fuc: L-fucose; Mann: D-mannose; Gal: D-galactose; ManNAc: N-acetyl-D-mannosamine; GlcNAc: N-acetyl-D-
glucosamine; GalNAc: N-acetyl-D-galactosamine.
—: not reported to date.
polypeptides. Each polypeptide consists of a short N-
terminal domain, a triple helical collagen domain of variable
length, a neck region, and a CRD (Figure 1). The neck
region induces polypeptide trimerization, which is further
stabilized by the collagen domain. Trimers can associate to
form higher-order multimeric complexes through disulﬁde-
stabilized interactions at the N-terminus, thereby increasing
binding avidity for microbes and other ligands [34]. MBL
and SP-A are commonly composed of six associated trimers
(octadecamers or 18-mers), which resemble a bouquet of
ﬂowers. In contrast, SP-D, conglutinin, and CL-46 are
assembled into dodecamers (12-mers) of four or more
trimeric subunits and form a cruciform-like structure. With
the exception of CL-P1, all collectins described to date show
ligand-bindingpreferenceforMan-typesugarsoverGal-type
sugars [23] (see Table 1). Several reviews provide detailed
description of the structural and functional features of the
collectins [23, 34–36]. In the current paper, we will focus on
the relevance of collectins to immunity during IAV infection.
NonspeciﬁcinhibitorsofIAV,ﬁrstdescribedinthe1940s,
have been classiﬁed as α, β,o rγ inhibitors based on their
chemical composition and properties (reviewed in [37]).
The ﬁrst evidence of the anti-IAV activities of collectins was
providedbyAndersetal.whodemonstratedthatβ inhibitors
in bovine and mouse serum were Ca2+-dependent mannose-
binding lectins that bound to glycans on the globular head
of IAV HA, thereby blocking the ability of the HA to
bind to sialylated cell-surface receptors [38]. Subsequent
studies identiﬁed conglutinin and MBL as the major β
inhibitors in bovine and mouse serum, respectively [39].
In contrast to the lectin-mediated actions of β inhibitors, γ
inhibitors are sialylated glycoproteins that act independently
of Ca2+ by competing with sialylated cell-surface receptors
for binding to HA [40, 41]. Today, collectins are known to
mediate a range of anti-IAV activities including (but not
limited to) inhibition of IAV HA and NA, neutralization of
virus infectivity, virus aggregation, increased IAV uptake by
neutrophils,andopsonizationofvirustoenhanceneutrophil
respiratory burst responses to IAV (see Table 2). As discussed
in this review, there is growing evidence deﬁning the role of
particular collectins in anti-IAV immunity and researchers
are now exploring their potential as therapeutic agents for
the treatment of IAV-associated disease.
3.1. SP-D. SP-D and SP-A are constitutively present in lung
ﬂuids of the respiratory tract, the major site of IAV infection.
SP-D acts as a classical β inhibitor and its CRDs bind to
mannose-richglycansexpressedonIAVHAandNA[42–44].
Incontrast,SP-AinhibitsIAVinaCa2+-independentmanner
by binding of viral HA to a sialylated glycan expressed within
the SP-A CRD, thereby blocking the ability of HA to interact
with cellular receptors [45]. Findings that (i) removal of
the SP-A glycan completely abrogated anti-IAV activity
and (ii) SP-A was eﬀective against the poorly glycosylated
A/PR/8/34 (PR8, H1N1) strain of IAV [46] are consistent
with SP-A acting as a γ inhibitor rather than a β-type lectin
inhibitor. Thus, SP-A and SP-D bind to similar regions on
the HA molecule but do so via distinct mechanisms. For
the purposes of this paper we will focus on lectin-mediated
recognition of IAV by SP-D.
Human inﬂuenza is primarily an infection of the upper
respiratorytractbutcanspreadtothelowerairwaysresulting
in viral pneumonia and/or predispose to secondary bacterial
infection. SP-D, present in nasal washings and bronchoalve-
olar ﬂuids (BALF) from na¨ ıve mice, is upregulated following
IAV infection and appears to be the major IAV inhibitor in
the airways of mice [44, 47–50]. Moreover, SP-D has been
shown to contributeto anti-IAV activity in BAL fromhealthy
human volunteers [42, 51] and to enhance aggregation
and neutrophil uptake of pathogens commonly associated
with secondary bacterial pneumonia such as Streptococcus
pneumoniae and Staphlococcus aureus [52].
SP-D preparations from diﬀerent species show varying
proportions of dodecamers (four homotrimeric subunits),
multimers of dodecamers, and/or single trimeric subunits
[53, 54]. The degree of oligomerization is an important fac-
tor modulating anti-IAV activity and dodecamers and multi-
mers exhibit greater antiviral activities than trimers [55–57].
In general terms, SP-D binds to Man-type oligosaccharides
(see Table 1) although the CRD from human, mouse, and ratJournal of Biomedicine and Biotechnology 5
Table 2: Summary of antiviral activities mediated by animal lectins against IAV.
Lectina HI NA inhibition Neutralization Aggregation Neutrophil Selected references
(i) ↑ uptake (ii) ↑ H2O2
hSP-D Yes Yes Yes Yes Yes Yes [42, 60, 61, 87]
hMBL Yes Yes Yes Yes Yes Yes [60, 85–88]
hCL-K1 — — Yes — — — [96]
bConglutinin Yes Yesb Yes Yes Yes Yes [39, 60, 105–107]
bCL-43 Yes Yes Yes No Yes No [60, 103, 115, 145]
bCL-46c Yes — Yes Yes Yes — [115, 116]
hGalectin-1 Yes — Yes — — — [28]
hSAP Yes — Yes — — — [32, 33]
aData reported for human (h) or bovine (b) lectins as indicated.
bReported using recombinant chimeric protein containing the N-terminus and collagen domain of rat SP-D expressed with the neck and CRD of conglutinin.
cReported using CL-46 NCRDs.
—: not reported to date.
SP-D showed distinct preferences for particular saccharide
ligands [54]. SP-D binds to glycans on the IAV enve-
lope glycoproteins to mediate hemagglutination inhibition
(HI), inhibition of NA activity, virus aggregation, and
neutralization of virus infectivity [42, 44, 58–60]( Table 2).
Binding of SP-D also promotes uptake of IAV by neutrophils
and protects neutrophils against IAV-induced neutrophil
dysfunction [42, 61]. However, neutrophil proteases can
cleave SP-D and chronic neutrophilic inﬂammation in the
airways may result in degradation of SP-D and account
for the increased risk of IAV infection associated with
heavy smoking or cystic ﬁbrosis [62, 63]. There are several
polymorphisms in the coding sequence of human SP-D,
including one at the codon corresponding to amino acid
residue 11 (Met11Thr). Moreover, the Thr/Thr11 variant
assembles as trimers rather than higher-order multimeric
species [64] and these display reduced anti-IAV activity in
vitro [56, 64].
SP-D binds directly to oligosaccharides expressed on
either IAV HA or NA [44, 59], yet the susceptibility of
diﬀerent IAV strains to SP-D correlates with the degree of
glycosylation of HA. Seasonal “drift” strains of H3N2 IAV
with increased glycosylation on the globular head of HA
were more susceptible to neutralization by SP-D and showed
reduced virulence in mice [44]. Furthermore, Hartshorn et
al. used hemagglutination inhibition (HI) assays to implicate
speciﬁc sites on the HA of H3N2 and H1N1 subtype IAV
as targets for recognition by recombinant human (Rh) SP-D
[58]. Recently, site-directed mutagenesis and reverse genetics
were utilized to deﬁne the contribution of speciﬁc glycans on
H3N2[50,65]andH1N1[66]IAVindeterminingsensitivity
to SP-D and to virulence in mice. Collectively, these studies
indicated that both the number and the position of potential
glycosylation sites on the globular head of the HA modulate
the avidity of SP-D binding and therefore the potency of
antiviral activity against diﬀerent IAV.
SP-D-deﬁcient mice (SP-D−/−) display aberrant pulmo-
nary surfactant homeostasis, including progressive pulmo-
nary inﬂammation, emphysema, macrophage activation,
and surfactant phospholipid accumulation [67–69]a n d
correction of alveolar homeostasis required the collage-
nous domain of SP-D [70, 71]. Following infection with
highly glycosylated IAV, SP-D−/− mice show increased virus
replication, airway inﬂammation, and disease [47, 48, 50]
(summarized in Table 3) and these eﬀects could be corrected
by overexpression of wild type or mutant SP-D proteins in
the airways [70]. Mannan, a complex polymer of mannose
residues, eﬃciently blocks the anti-IAV activities of SP-D
in vitro and intranasal treatment of wild-type mice with
mannan prior to and during infection with a highly glycosy-
lated H3N2 IAV strain resulted in enhanced viral replication,
pulmonary inﬂammation, and death [49]. Studies in a
mouse model have also suggested that compromise of SP-
D-mediated defenses by elevated glucose levels might be
an important factor contributing to the increased disease
severity of IAV-induced disease in diabetic mice [72].
3.2. MBL. MBL binds to oligosaccharides with characteristic
chemical and spatial features that are expressed on the
surface of a wide range of pathogens, including bacteria,
fungi, and viruses (reviewed in [73]). In general terms, MBL
recognizes Man-type sugars and Haurum et al. reported
that MBL binding to mannan was inhibited by monosac-
charides such as GlcNAc, mannose, L-fucose, and N-acetyl-
mannosaminebutnotbygalactoseorGalNAc[74](Table 1).
Following binding to pathogens, MBL can activate the lectin
complement pathway via MBL-associated serine proteases
(MASPs), resulting in complement-mediated lysis and/or
opsonophagocytosis [75, 76]. Binding of MBL-MASP com-
plexes to appropriate ligands also activates coagulation via
thrombin-like activity [77, 78]. MBL is unique among the
collectins in its ability to activate complement and coag-
ulation.
Although humans express a single MBL gene, two homo-
logousformsofMBL,termedMBL-AandMBL-C,havebeen
identiﬁed in rodents [79, 80]. These two forms of rodent
MBL are 50% homologous, display distinct but overlapping
ligand-binding speciﬁcity, and bind to MASPs to activate
complement [81]. Multiple structural and promoter poly-
morphisms in the human MBL2 gene can result in low levels6 Journal of Biomedicine and Biotechnology
Table 3: Virulence of diﬀerent IAVs in mice genetically deﬁcient in particular animal lectins.
Mice
deﬁcient in IAV straina Susceptibility to
IAV infection
Virus growth
in lungs Comments References
SP-D Phil/82 ↑↑ ↑ lung inﬂammation [47, 48]
Phil/82Δ167 ND ND Lacking Asn165 = less sensitive to SP-D [47]
Mem71 ND ND Strain less sensitive to SP-D than Phil/82 [48]
MBL-A/C Phil/82 ↑↑ ↑ inﬂammation and lung injury [84]
Cal/09 ↓ ND ↓inﬂammation and lung injury [93]
H9N2/G1 ↓↓ ↓ inﬂammation and lung injury [93]
Galectin-1 WSN/33 ↑ — HI and neutralization against IAV in vitro [28]
SAP PR8, WS/33,
Shg/24 ND ND HI and neutralization against IAV in vitro [133]
aIAV strains used: A/Philippines/82 (Phil/82, H3N2); A/Mem71H-BelN (Mem/71, H3N1); A/WSN/33 (WSN/33, H1N1); A/PR/8/34 (PR8, H1N1), A/WS/33
(WS/33, H1N1), A/California/04/09 (Cal/09, H1N1 pdm), A/Shanghai/24/90 (Shg/24, H3N2), A/Quail/Hong Kong/61/97 (H9N2/G1).
↑, ↓, or ND: increased, decreased, or not diﬀerent to wild-type mice, respectively.
—: not reported to date.
and/or dysfunctional MBL. Moreover, MBL deﬁciency has
been associated with predisposition to numerous infectious
diseases, including respiratory infections (reviewed in [82]).
SP-A and SP-D are constitutively expressed in the lungs
whereas MBL is predominantly a serum protein. MBL is
rarely detected in BALF from healthy humans or mice,
although signiﬁcant levels have been detected during airway
inﬂammation [83], including that associated with IAV infec-
tion of mice [44]. Recently, aﬃnity puriﬁcation and western
blot conﬁrmed the presence of MBL in BALF from healthy
mice,albeitatlevelsthatwerebelowdetectionbyELISA[84].
MBL has been reported to mediate a range of anti-
IAV activities in vitro, including inhibition of virus-induced
hemagglutination [85, 86], blocking of NA enzymatic activ-
ity [60, 87], opsonization for enhanced neutrophil reactivity
to IAV [85, 86], and neutralization of virus infectivity
[84, 86–88]( Table 2). These activities are complement-inde-
pendent and shared by other mammalian collectins such as
SP-Dandconglutinin.Inaddition,MBL-mediatedactivation
of complement can induce irreversible inactivation of IAV
[89] and promote lysis of IAV-infected cells [90]. Chang et al.
recently reported that recombinant human MBL (RhMBL)
and murine MBL-A/-C could neutralize IAV infectivity
but that preferential activation of the lectin complement
pathway and thrombin-like activity by MBL-A and MBL-
C,respectively,wasassociatedwithenhancedMBL-mediated
neutralization [84].
Lectin blot analysis indicates that MBL can bind to
both HA and NA glycoproteins [44, 88, 91], yet as for SP-
D, the degree of glycosylation on the head of IAV HA is
the critical factor determining sensitivity to MBL. Seasonal
H1N1IAVsexpressing3-4potentialglycosylationsitesonthe
head of HA were more sensitive to neutralization by RhMBL
compared to poorly glycosylated strains such as PR8 (H1N1)
or A/California/04/09 (Cal/09, A(H1N1) 2009 pdm) [87].
Similarly, H3N2 IAVs carrying 4-5 potential glycosylation
sites on the head of HA were highly sensitive to MBL in
mouse serum [44]. Current evidence suggests that inhibition
of NA activity also results from steric hindrance of the active
site of NA by SP-D/MBL bound to mannose-rich glycans on
the viral HA [44, 60, 87].
The role of MBL in vivo during IAV infections remains
controversial. Chang et al. reported MBL-deﬁcient mice to
be more susceptible to A/Philippines/82 (Phil/82, H3N2), a
highly glycosylated IAV strain that is readily neutralized by
MBL [84]( Table 3). MBL showed some binding to A(H1N1)
2009 pdm, yet these viruses were resistant to MBL-mediated
neutralization [87, 92] and MBL-null mice infected with
A(H1N1) 2009 pdm (or H9N2/G1) IAV showed reduced
disease severity and airway inﬂammation [93]( Table 3),
arguing that MBL may be a risk factor during certain IAV
infections. Thus, high avidity interaction between MBL and
IAV may result in protective antiviral responses whereas
low avidity binding may be insuﬃcient to mediate anti-
IAV function, resulting in detrimental MBL-induced pro-
inﬂammatory responses and severe disease.
3.3.OtherCollectins. Inadditionto“classicalcollectins”such
as SP-D and MBL, much less is known regarding the general
structure and function of “novel collectins” such as CL-L1,
CL-P1, and CL-K1 (collectin 11) and there are limited data
regarding their role in anti-IAV immunity. CL-L1, predomi-
nantly produced by the liver, is a cytosolic protein with weak
lectin function[94]s ugg es ti n gad i ﬀerent biological function
to that of the classical collectins. CL-P1, a membrane-
associated collectin, is expressed on vascular endothelial cells
and recognizes oxidized low-density lipoprotein as well as
bacteria and yeasts [95]. To date, no interactions between
IAV and CL-L1 or CL-P1 have been reported. Collectin
11, a MASP-associated plasma lectin, was recently shown
to inhibit IAV-induced hemagglutination and to neutralize
virus infectivity [96]. Moreover, collectin 11 is expressed in
airway bronchioles [97] and as a circulating plasma protein
[96, 98] and may therefore represent an innate barrier to
IAV infection and/or transude from the plasma to inﬂamed
airways in a manner analogous to that reported for MBL
[44, 83].Journal of Biomedicine and Biotechnology 7
3.4. Bovine, Porcine, and Avian Collectins
3.4.1. Bovine Collectins. Conglutinin was the ﬁrst described
lectin of animal origin and was originally discovered by its
ability to agglutinate (conglutinate) erythrocytes coated with
antibody and complement [99]. It is distinct from other
collectins as it binds iC3b, a component of the comple-
ment pathway [100, 101]. While most collectins have been
identiﬁed in multiple species, conglutinin, CL-43, and CL-
46 appear to be restricted to the species Bovidae and
characterization of their respective genes indicates that they
aredescendantsofanancestralSP-Dgene[102].Conglutinin
and CL-46 form dodecameric structures similar to those of
SP-D whereas CL-43 occurs naturally as trimers [102–104].
The evolutionary pressures that have resulted in the presence
of additional collectins in Bovidae are not known. Hartshorn
et al. proposed that the combined anti-IAV activities of
conglutinin, CL-43, and CL-46 might explain why cattle do
not represent a natural reservoir for IAV infection, despite
living in close proximity to other natural hosts of IAV, such
as birds, pigs, horses, and humans [103].
Conglutininactsasa β inhibitorofIAV,bindingtooligo-
saccharides on the tip of the HA spike in a Ca2+-dependent
manner[39,105]toinhibitvirus-inducedhemagglutination,
aggregation, and neutralization of virus infectivity [39, 105–
109](Table 2).Opsonization withconglutinin alsoenhanced
neutrophil respiratory burst responses after exposure to IAV
[107]. Lectin blot studies have demonstrated that MBL and
SP-D bind to both HA and NA, yet conglutinin binds only
to HA [88, 106, 110, 111], and this has been proposed as one
factorcontributingtoitsrelativelypoorabilitytoinhibitviral
spreading to adjacent cells [108]. Of the diﬀerent IAV strains
and subtypes tested, most H1N1 and H3N2 subtypes were
susceptible to conglutinin with the exception of the poorly
glycosylated PR8 (H1N1) strain [39, 105, 107]. Mutants of
H3N2 or H1N1 IAV lacking a single glycosylation site from
the tip of the HA spike (Asn165-H3 numbering or Asn104-
H1 numbering, respectively) were also markedly resistant to
conglutinin [38, 39].
CL-43, like conglutinin, is a potent inhibitor of IAV;
however this lectin exhibits distinct monosaccharide binding
properties [112] (see Table 1)a n df o r m st r i m e r sb u tn o t
other high-order multimers [113]. The potency of various
SP-D preparations in mediating HI and virus neutralization
has been strongly associated with its degree of multimer-
ization [85, 114], yet trimers of CL-43 mediated HI and
neutralizing activity against IAV to levels equivalent to those
of fully multimerized SP-D and were markedly more potent
than trimeric SP-D preparations [103]. Collectin-induced
aggregation of IAV has also been strongly associated with the
abilityofSP-D,MBL,orconglutininpreparationstoenhance
neutrophil respiratory burst responses and to increase neu-
trophil uptake of IAV [61, 85]. CL-43 did not induce viral
aggregation and did not enhance IAV-induced generation of
H2O2;howeverneutrophiluptakeofIAVwasincreased[103]
(Table 2), most likely via mechanisms distinct to those of
other collectins. Recently, trimers composed of the neck and
CRD (NCRD) of CL-46 were also shown to neutralize IAV
infectivity, inhibit virus-induced hemagglutination, induce
aggregation of IAV, and to increase neutrophil uptake of IAV
[115, 116].
3.4.2. Porcine SP-D. Porcine (p)SP-D is unique amongst the
mammalian SP-Ds described to date in that it contains a
sialic acid-rich N-glycan in its CRD [117, 118]. Human
and porcine SP-A also express sialylated N-glycans in their
respective CRDs and mediate Ca2+-independent anti-IAV
activity that was abrogated by the removal of this glycan
[45, 118]. In contrast, pSP-D displayed dual mechanisms of
anti-IAV activity by mediating (i) Ca2+-dependent binding
of the pSP-D CRD to oligosaccharides of IAV HA, and
(ii) binding of IAV HA to sialic acid expressed by pSP-D.
Initial binding of pSP-D to mannose-rich glycans on HA
appears to be critical and secondary interactions between
IAV HA and sialylated glycans on pSP-D do not take place
in the absence of lectin-mediated binding [117, 118]. The
sialylated glycan expressed on pSP-D was shown to enhance
virus aggregation and neutralization as well as neutrophil
responses to IAV [118]. Accordingly, pSP-D isolated from
porcine BAL and recombinant pSP-D displayed more potent
anti-IAV activity compared to human or rat SP-D and were
active against a broader spectrum of IAV strains [118, 119].
Together these data suggest that pulmonary innate defenses
ma ybeparticularlyeﬃcientagainstIAVinpigsandrepresent
an important barrier limiting disease severity. IAV strains
show limited antigenic variation in swine compared to
humans [120], and this may reﬂect the shorter lifespan of
farmed animals. Moreover, restriction of IAV infection by
porcine innate defenses might also limit the induction of
antibody-mediated adaptive immune responses in pigs that
are required to drive antigenic drift.
3.4.3. Chicken Collectins. Avian species, including domestic
poultry, represent an important natural reservoir for IAV
infection. Ducks, chickens, and turkeys may all be farmed
in close proximity to humans and other IAV reservoirs
including pigs and horses, thereby increasing the potential
for interspecies transmission. It is well established that
mammalian collectins mediate anti-IAV activity. In chickens,
5 collectins have been described to date, namely, MBL [121],
SP-A (cSP-A), and chicken collectins 1, 2, and 3 (cCL-1,
-2 and -3) which resemble the mammalian proteins CL-
L1, collectin 11, and CL-P1, respectively [122]. In addition,
chickenlunglectin(cLL)wasidentiﬁedasaC-typelectinbut
not as a collectin due to its lack of a collagenous domain
[122]. Phylogenetic analyses suggest that the homologue
of mammalian SP-D has been deleted in chickens and
that a bird-speciﬁc duplication of the SP-A gene may have
given rise to cLL [123]. cLL inhibited the hemagglutination
activity of Phil/82 (H3N2; highly glycosylated HA) and
PR8 (H1N1; poorly glycosylated HA) to similar levels but
did not neutralize either virus strain [124]. At present the
mechanisms underlying cLL-IAV interactions are not fully
understoodandfurtherstudies arerequiredtodetermine the
role of avian collectins in anti-IAV immunity.8 Journal of Biomedicine and Biotechnology
4.Other Mammalian Lectinswith
Anti-Inﬂuenza Activity
Galectins are S-type animal lectins characterized by a con-
served CRD that recognizes galactose-containing oligosac-
charides. Recently, lectin-mediated binding of galectin-1 to
IAVwasshowntoinhibitIAV-inducedhemagglutinationand
to reduce virus production in MDCK cells [28]. Galectin-
1 bound to a range of IAV subtypes (H1N1, H2N2, H3N2,
H5N2, and H6N1) with micromolar Kd values suggesting
broad antiviral activity and binding was inhibited by lactose,
but not by mannose (Table 1). Importantly, galectin-1 was
upregulated in the lungs of IAV-infected mice and mice
lacking endogenous galectin-1 showed reduced survival
comparedtowild-typemice[28].Together,thesedataarethe
ﬁrst to demonstrate the importance of galectins in anti-IAV
immunity.
The short pentraxin SAP has been reported to act
as a β inhibitor against IAV, binding in a Ca2+-dependent
manner to glycans on the viral HA to mediate HI and
neutralize virus infectivity [32, 33]( Table 2). In vitro,h u m a n
SAP inhibited a range of type A (H1N1, H2N2, and H3N2)
and type B viruses and antiviral activity was blocked by
the inclusion of mannose, consistent with recognition of
Man-type glycans on the IAV. PTX3 also mediates anti-IAV
activity; however this appears to be mediated by binding
of the IAV HA to SA residues expressed on PTX3 [125]i n
a manner analogous to that described for SP-A. As lectin-
mediated recognition of IAV by PTX3 does not appear to
contribute to its anti-IAV activity, it will not be discussed
further in this paper.
5. Pandemic IAV andLectin-MediatedDefenses
When pandemic IAVs ﬁrst emerge, they generally carry little
glycosylation on the head of HA but acquire additional
glycosylation sites as they continue to circulate in the human
population. In 1968, H3N2 IAV associated with “Hong Kong
ﬂu” carried 2 potential glycosylation sites on the HA head
whereas recent H3N2 viruses carry 6 to 7 sites [50, 58].
Pandemic H1N1 strains associated with the 1918 “Spanish
ﬂu” had only 1 potential glycosylation site (Asn104) on the
globular head of HA but by the 1950s had acquired a total
of 4 to 5 sites [17, 18, 126]. Asn104 was also the only site
expressed on the head of HA of A(H1N1) 2009 pdm viruses
associated with the 2009 “Swine ﬂu” pandemic [17, 87, 126]
and few variants with altered HA glycosylation have been
detected to date [18]. In the future it is likely that A(H1N1)
pdm viruses will develop resistance to the current vaccine,
perhaps through the evolution of mutants with altered HA
glycosylation patterns that favour resistance to preexisting
neutralizing antibodies.
The degree of glycosylation on the globular head of HA
is a critical factor in determining sensitivity of diﬀerent IAV
strains to the antiviral activities of collectins. Consequently,
pandemic IAVs tend to be resistant to collectins when com-
pared to seasonal IAV strains. For example, human SP-D
and MBL inhibited IAV-induced hemagglutinating activity,
blocked the enzymatic activity of NA, and neutralized the
infectivity of seasonal H1N1, but not pandemic A(H1N1)
2009 pdm IAV [87]. Chimeric viruses expressing the HA of
1918 (H1), 1957 (H2), 1968 (H3), and 2009 (H1) pandemic
IAV in the context of a seasonal H1N1 IAV were poorly
recognized by RhSP-D in vitro and were associated with
enhanced lower respiratory tract pathology in IAV-infected
mice [127], consistent with the notion that sensitivity to
SP-D might limit the ability of IAV to invade the lower
airways and induce severe disease. In the mouse model, weak
interactions between MBL and A(H1N1) 2009 pdm viruses
have also been implicated in the induction of MBL-induced
proinﬂammatory responses, suggesting that MBL might be
a risk factor associated with severe disease during pandemic
IAV infections [93]. However, no association was observed
between phenotypic MBL deﬁciency and predisposition to
A(H1N1) 2009 pdm in exposed health care workers [128].
Highly pathogenic avian inﬂuenza (HPAI) H5N1 IAV
infections have been associated with very severe disease and
fatality in humans and are still considered to be a potentially
serious pandemic threat [129]. Microarray analysis and
quantitative RT-PCR showed SP-D expression to be reduced
in lungs from two fatal cases of H5N1 IAV infection
when compared to healthy patients or patients with acute
respiratory distress syndrome [130], although other studies
noted no major changes in SP-D expression in the airways of
H5N1-infected ferrets [131]o rm a c a q u e s[ 132]. In addition,
2humanH5N1strainsthatwerelessglycosylatedthanrecent
seasonal H1N1 and H3N2 strains were also resistant to
SP-D in vitro [58], consistent with the notion that SP-D-
mediated defenses may be ineﬀective against H5N1 strains.
Future studies will determine the susceptibility of a range
of diﬀe r e n ta v i a nI A Vt oS P - Da sw e l la st h ep o t e n t i a lo f
animal lectins as prophylactic and/or therapeutic treatments
during severe H5N1-induced disease. As noted previously,
lectins are expressed in the respiratory and digestive systems
of chickens. As these are the major sites of IAV replication
and dissemination, understanding their role in avian host
defense is particularly important as they may act to control
disease and limit viral transmission.
6. Therapeutic Potential of Recombinant
AnimalLectinsduringIAV Infection
Understanding mechanisms by which mammalian lectins
mediate antiviral activity against IAV is an important ﬁrst
step towards development of novel lectin-based therapeu-
tic and prophylactic agents. Treatment of lectin-deﬁcient
mice with puriﬁed recombinant lectins can reverse the
enhanced susceptibility associated with IAV infection. For
example, intraperitoneal injection of RhMBL or intratra-
cheal administration of RhSP-D reduced titres of Phil/82
in the lungs of MBL null mice [84]o rS P - Dn u l lm i c e
[48], respectively, to levels equivalent to those of wild-type
animals. Yang et al. demonstrated that intranasal treatment
of IAV-infected C57BL/6 mice with recombinant galectin-1
enhanced survival, reduced viral load, and attenuated lungJournal of Biomedicine and Biotechnology 9
inﬂammation and injury [28]. In addition, intranasal treat-
mentofBALB/cmicewithhumanSAP1hrpriortoinfection
with A/Japan/57 (Jap/57, H2N2) reduced disease severity
[33] although Herbert et al. reported that intraperitoneal
injection of C57BL/6 mice with human SAP had no eﬀect on
disease outcome [133]. The particular route of lectin admin-
istration will be one factor modulating the eﬀectiveness
of exogenous animal lectins in ameliorating IAV-associated
disease. Moreover, IAV strains show major diﬀerences in
susceptibility to animal lectins [44, 50, 58], highlighting
the importance of assessing therapeutic and/or prophylactic
potential against a range of seasonal and pandemic IAV
strains.
6.1. Recombinant Chimeric Lectins (RCLs). RCLs represent a
tailored approach exploiting particular anti-IAV properties
of diﬀerent pattern recognition molecules. For example,
chimeric lectins comprising the collagenous domain of SP-
D in conjunction with the neck and CRD of MBL displayed
more potent anti-IAV activities compared to either SP-
D or MBL alone [114, 134]. Similarly, expression of the
conglutinin neck and CRD domains in conjunction with
the collagenous domain of SP-D resulted in increased anti-
IAV activity [43]. An RCL bearing the CRD of MBL and
the collagenous domains of L-ﬁcolin (an additional innate
pattern recognition receptor) showed enhanced activation of
the lectin complement pathway and anti-IAV activity as well
as reduced thrombin-like and FXa-like coagulation enzyme
activities compared to RhMBL alone [135], representing
further reﬁnement towards potent therapeutics against IAV
which might display reduced side eﬀects in a clinical setting.
6.2. Recombinant Truncated Lectins. Recombinant truncated
NCRD trimers of SP-D represent an appealing therapeutic
option as they can be produced in large quantities and
lack the collagen domain associated with potential pro-
inﬂammatory eﬀects of SP-D [136]. However, NCRDs of
human or rodent SP-D bound eﬀectively to various SP-D lig-
ands but displayed only weak inhibitory activity against IAV
in vitro [54–56, 137]. Subsequent studies demonstrated that
cross-linking of NCRDs and/or mutagenesis of speciﬁc CRD
residues represent complimentary strategies that enhanced
anti-IAV activity of SP-D NCRDs [138, 139]. The lectin
domains of serum collectin NCRDs (e.g., MBL, conglutinin,
CL-43, or CL-46) show intrinsically greater anti-IAV activity
comparedtotheNCRDsofSP -D[43,103,134].Forexample,
CL-43 NCRDs were more potent than SP-D NCRDs and CL-
43 showed a distinctive three amino acid insertion (RAK) in
the ﬂanking region of the carbohydrate binding site that was
absent in SP-D. Insertion of 3 amino acids (RAK or AAA)
into the SP-D NCRD enhanced anti-IAV activity relative to
the wild-type SP-D NCRD [115, 137].
Alignment of serum collectins with SP-D has also re-
vealed nonconservative substitutions at amino acid positions
325 and 343 which are highly exposed on opposing ridges of
the carbohydrate-binding groove [140]. Recent studies have
substituted these residues (alone or in combination) into
the SP-D NCRD in an attempt to enhance ligand binding
and anti-IAV activity [54, 116, 138, 140]. Crouch et al.
recently demonstrated that a mutant of the human SP-D
NCRD that contained 2 amino acid substitutions (D325A +
R343V) displayed enhanced anti-IAV activity in vitro com-
pared to mutants which expressed either substitution alone
[140]. Moreover, intratracheal coadministration of D325A
+ R343V NCRD reduced morbidity and increased viral
clearance in mice infected with a reassortant of A/WSN/33
bearing a glycosylated HA, demonstrating the potential of
exogenous recombinant NCRD preparations to enhance
antiviral activity and reduce disease severity in vivo.
6.3. Recombinant Lectins with Modiﬁed N-Glycans. pSP-D is
unique in that it is the only SP-D species known to carry
a sialylated sugar in its CRD domain [117]. Simultaneous
binding of the CRD to glycans on HA/NA of IAV as well as
HA-mediated recognition of terminal SA on the N-glycan
expressed by the pSP-D CRD enhances antiviral activity
and broadens the range of virus strains inhibited by pSP-D
[118]. Recently, van Eijk et al. produced functionally active
recombinant pSP-D (RpSP-D) and attempted to enhance
the anti-IAV properties of recombinant hSP-D (RhSP-D)
by introducing N-linked glycans into its CRD [141]. RpSP-
D displayed more potent anti-IAV activity than RhSP-D
but introduction of an SA-rich glycan at the same location
as in the CRD of pSP-D did not enhance the anti-IAV
activity of RhSP-D. Moreover, introduction of glycans at
othersiteswithintheCRDofRhSP-Dinterferedwithprotein
secretion and/or lectin function. Therefore, further studies
are required to determine the most eﬀective manner in
which glycan modiﬁcation within the CRD can be utilized to
augment lectin-mediated recognition and anti-IAV activities
of RhSP-D.
7. Conclusions
It is clear that endogenous lectins are important contributors
to pulmonary defense against IAV via direct recognition of
free virus (and virus-infected cells) as well as modulating
airway inﬂammation and disease. While classical collectins
such as MBL and SP-D have been studied in detail, much less
isknownregardingantiviralactivitiesofothercollectinssuch
as CL-L1, CL-K1 (collectin 11) and avian lectins, or the role
that they might play in vivo. Recent ﬁndings that chickens
lack SP-D but contain an additional lectin (cLL) [123]a n d
that pig SP-D contains unique structural features, including
an extra glycosylation site in its CRD [118], highlight
the importance of understanding species diﬀerences and
particular biochemical features that can modulate the anti-
IAV activity of endogenous lectins. This in turn will inform
the development of highly eﬀective novel lectin constructs
that may be used eﬀectively to prevent and/or treat inﬂuenza
infections in humans. Finally, understanding the role of
endogenous lectins in natural reservoirs (including humans,
pigs and avian species) and animal models (e.g., ferrets
and mice) of IAV infection will aid in our understanding
of factors that may limit interspecies transmission of IAV
and/or modulate disease severity.10 Journal of Biomedicine and Biotechnology
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